Literature DB >> 18608206

TLR4 signaling induces B7-H1 expression through MAPK pathways in bladder cancer cells.

Yigang Qian1, Junfang Deng, Lei Geng, Haiyang Xie, Guoping Jiang, Lin Zhou, Yan Wang, Shenyong Yin, Xiaowen Feng, Junwei Liu, Zhou Ye, Shusen Zheng.   

Abstract

TLR4 (Toll-like receptor 4) and B7-H1, which were known to be restricted to immune cells in the past, were found to be aberrantly expressed in a majority of tumor cells, facilitating tumor evasion from immune surveillance. Our study demonstrated that activation of TLR4 signaling in bladder cancer cells up-regulated B7-H1 expression. Furthermore, this regulation was significantly attenuated by ERK or JNK inhibitor. Our results elucidated the molecule mechanism of regulation of B7-H1 expression through TLR4 signaling and may suggest new strategies of down-regulating the cancer-associated B7-H1 expression for bladder cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18608206     DOI: 10.1080/07357900801941852

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  43 in total

Review 1.  T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.

Authors:  Yael S Barach; Jun Sik Lee; Xingxing Zang
Journal:  Trends Mol Med       Date:  2011-01       Impact factor: 11.951

2.  PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast.

Authors:  Elizabeth D Thompson; Janis M Taube; Rebecca J Asch-Kendrick; Aleksandra Ogurtsova; Haiying Xu; Rajni Sharma; Alan Meeker; Pedram Argani; Leisha A Emens; Ashley Cimino-Mathews
Journal:  Mod Pathol       Date:  2017-07-21       Impact factor: 7.842

3.  Aberrant upregulation of PDK1 in ovarian cancer cells impairs CD8+ T cell function and survival through elevation of PD-L1.

Authors:  Jing-Jing Wang; Michelle K Siu; Yu-Xin Jiang; Thomas H Leung; David W Chan; Ran-Ran Cheng; Annie N Cheung; Hextan Y Ngan; Karen K Chan
Journal:  Oncoimmunology       Date:  2019-09-05       Impact factor: 8.110

Review 4.  Immunosuppression associated with chronic inflammation in the tumor microenvironment.

Authors:  Dingzhi Wang; Raymond N DuBois
Journal:  Carcinogenesis       Date:  2015-09-08       Impact factor: 4.944

Review 5.  Regulation and Function of the PD-L1 Checkpoint.

Authors:  Chong Sun; Riccardo Mezzadra; Ton N Schumacher
Journal:  Immunity       Date:  2018-03-20       Impact factor: 31.745

6.  TLR4 mediates MAPK-STAT3 axis activation in bladder epithelial cells.

Authors:  Huang Ying; Liu Da; Shi Yu-xiu; Xia Yu; Liu Li-xia; Xie Li-mei; Ren Wei-dong
Journal:  Inflammation       Date:  2013-10       Impact factor: 4.092

7.  In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors.

Authors:  Céline Berthon; Virginie Driss; Jizhong Liu; Klaudia Kuranda; Xavier Leleu; Nathalie Jouy; Dominique Hetuin; Bruno Quesnel
Journal:  Cancer Immunol Immunother       Date:  2010-09-04       Impact factor: 6.968

8.  Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models.

Authors:  Emily A Lanzel; M Paula Gomez Hernandez; Amber M Bates; Christopher N Treinen; Emily E Starman; Carol L Fischer; Deepak Parashar; Janet M Guthmiller; Georgia K Johnson; Taher Abbasi; Shireen Vali; Kim A Brogden
Journal:  Cancer Immunol Immunother       Date:  2016-09-29       Impact factor: 6.968

9.  Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer.

Authors:  Naoki Takahashi; Satoru Iwasa; Yusuke Sasaki; Hirokazu Shoji; Yoshitaka Honma; Atsuo Takashima; Natsuko Tsuda Okita; Ken Kato; Tetsuya Hamaguchi; Yasuhide Yamada
Journal:  J Cancer Res Clin Oncol       Date:  2016-06-02       Impact factor: 4.553

Review 10.  Toll-like receptors in urothelial cells--targets for cancer immunotherapy.

Authors:  Hélène LaRue; Cherifa Ayari; Alain Bergeron; Yves Fradet
Journal:  Nat Rev Urol       Date:  2013-08-27       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.